News | October 21, 2009

Raydiance Achieves Breakthrough for Manufacturing Bioabsorbable Stents

This bioabsorbable stent with 80 micron struts and 3.5 mm diameter was machined with Raydiance Smart Light, the world's only commercial grade ultrafast laser platform.

October 21, 2009 – Raydiance Corp., developer of the world’s first commercial-grade ultrafast laser, said today it made a major breakthrough in manufacturing a wide variety of bioabsorbable materials with precise, micron-resolution feature sizes and with no heat affected zones (HAZ).

Raydiance has been deploying its Smart Light MD platform with leading medical device companies to manufacture a range of bioabsorbable vascular stent designs and materials, as well as other biocompatible polymers.

The recent Raydiance work was performed on bioabsorbable materials such as polylactic acid, polyglycolic acid, and a variety of copolymers. The vascular stents machined by Raydiance had strut dimensions of 80 microns and less.

“The medical device industry has embarked on an exciting wave of innovation in small, extremely precise implantable devices,” said Scott Davison, president of Raydiance. “These new products and applications require a new tool that enables the machining of very small features without introducing heat to the process. Raydiance Smart Light is that tool.”

Raydiance will discuss this advance at the Medical Design and Manufacturing show in Minneapolis today and tomorrow.

For more information: www.raydiance-inc.com

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Tryton Medical, Side Branch Stent, first U.S. commercial case, New York-Presbyterian Hospital, Columbia University Medical Center
News | Stents Bifurcation| March 31, 2017
Tryton Medical Inc. recently announced that the first U.S. commercial case using the Tryton Side Branch Stent was...
Sponsored Content | Videos | Stents Bioresorbable| March 30, 2017
Stephen Ellis, M.D., professor of medicine and director of interventional cardiology at Cleveland Clinic, discusses t
Overlay Init